Anna Saborowski

4.5k total citations · 1 hit paper
57 papers, 2.5k citations indexed

About

Anna Saborowski is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anna Saborowski has authored 57 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Surgery, 23 papers in Oncology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anna Saborowski's work include Cholangiocarcinoma and Gallbladder Cancer Studies (24 papers), Hepatocellular Carcinoma Treatment and Prognosis (13 papers) and Gallbladder and Bile Duct Disorders (11 papers). Anna Saborowski is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (24 papers), Hepatocellular Carcinoma Treatment and Prognosis (13 papers) and Gallbladder and Bile Duct Disorders (11 papers). Anna Saborowski collaborates with scholars based in Germany, United States and Canada. Anna Saborowski's co-authors include Arndt Vogel, Gonzalo Sapisochín, Tim Meyer, Riad Salem, Arndt Vogel, Scott W. Lowe, Michael Saborowski, Oreste Segatto, Monika A. Davare and Brian Druker and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Anna Saborowski

52 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatocellular carcinoma

2022 1.3k citations Arndt Vogel, Gonzalo Sapisochín et al. profile →

Peers

Countries citing papers authored by Anna Saborowski

Since Specialization

Citations

This map shows the geographic impact of Anna Saborowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Saborowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Saborowski more than expected).

Fields of papers citing papers by Anna Saborowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Saborowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Saborowski. The network helps show where Anna Saborowski may publish in the future.

Co-authorship network of co-authors of Anna Saborowski

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Saborowski. A scholar is included among the top collaborators of Anna Saborowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Saborowski. Anna Saborowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Two-Stage Hepatectomy for Cholangiocarcinoma Under Total Vascular Exclusion with Veno-venous ECMO Bypass and Controlled Closed-loop In Situ Hypothermic Oxygenated Perfusion of the Liver: The Hannover CLIP-Concept 2025 ·Annals of Surgical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), C. Kühn, (unknown), Anna Saborowski, Björn Hartleben, (unknown), Markus Quante, Tung Yu Tsui, Moritz Schmelzle	1
2	Navigating second-line therapy after immunotherapy in advanced HCC☆ 2025 ·JHEP Reports ·Arndt Vogel, Anna Saborowski, Lorenza Rimassa, Anthony B. El-Khoueiry	1
3	Improving gastrointestinal cancer therapy by uniting stakeholders 2024 ·SHILAP Revista de lepidopterología ·Michael Quante, Anna Saborowski, C. Benedikt Westphalen	1
4	Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data 2024 ·JHEP Reports ·Zhihao Li, Daniel Aliseda, Owen Jones, Luckshi Rajendran, (unknown), Robert Grant, Grainne M. O’Kane, Anna Saborowski, Gonzalo Sapisochín, Arndt Vogel	3
5	58P Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials 2024 ·Annals of Oncology ·(unknown), Anna Saborowski, Jaewon Hyung, (unknown), Il Hwan Kim, Henning Wege, Kwang Pyo Kim, Gunnar Folprecht, B-Y. Ryoo, (unknown), Jun Cheon, Thorsten Oliver Goetze, Hyewon Ryu, (unknown), Arndt Vogel	0
6	Die Modelltransferierbarkeit von KI in der digitalen Pathologie 2024 ·PubMed ·(unknown), (unknown), (unknown), (unknown), Paul K. Ziegler, Anna Saborowski, Henning Reis, Arndt Vogel, Peter J. Wild, Nadine Flinner	0
7	Association of RNF43 Genetic Alterations With BRAF^V600E and MSI^high in Colorectal Cancer 2024 ·JCO Precision Oncology ·Arndt Vogel, Karthikeyan Murugesan, (unknown), Júlia C.F. Quintanilha, Jeffrey S. Ross, Tilman Brummer, Anna Saborowski	2
8	955P IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma 2023 ·Annals of Oncology ·Arndt Vogel, Anna Saborowski, Gabriele Margareta Siegler, Jürgen Siebler, Udo Lindig, Maximilian Schultheiß, Thomas Mueller, (unknown), (unknown), David W.M. Muller, S-E. Al-Batran, (unknown)	1
9	IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early-stage hepatocellular carcinoma (HCC). 2023 ·Journal of Clinical Oncology ·Arndt Vogel, Oliver Waidmann, Tobias Müller, Gabriele Margareta Siegler, Thorsten Oliver Goetze, Enrico N. De Toni, Maria A. González-Carmona, (unknown), Michael Geißler, Ludwig Fischer von Weikersthal, (unknown), Fabian Finkelmeier, (unknown), Jens U. Marquardt, Andreas Teufel, (unknown), (unknown), Salah-Eddin Al-Batran, Anna Saborowski	4
10	Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma 2022 ·Journal of Hepatology ·(unknown), Karthikeyan Murugesan, Tilman Brummer, Oreste Segatto, Anna Saborowski, Arndt Vogel	81
11	New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option 2022 ·Clinical & Experimental Metastasis ·(unknown), Lena S. Becker, (unknown), Sabine Maschke, Frank Wacker, Anna Saborowski, Arndt Vogel, Jan B. Hinrichs	2
12	The Co‐mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion‐Driven Cholangiocarcinoma 2021 ·Hepatology ·(unknown), Silke Marhenke, (unknown), Diana Becker, (unknown), Tanja Poth, Karthikeyan Murugesan, Florian Kühnel, Norman Woller, Ralph M. Wirtz, Andreas Pich, Jens U. Marquardt, Michael Saborowski, Arndt Vogel, Anna Saborowski	14
13	LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) 2021 ·Annals of Oncology ·Arndt Vogel, Anna Saborowski, (unknown), Thomas J. Ettrich, Ursula Ehmer, Uwe M. Martens, (unknown), (unknown), Thomas Berg, Michael Geißler, (unknown), Martha M. Kirstein, Dirk Waldschmidt	8
14	Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma 2021 ·Trends in cancer ·Anna Saborowski, Arndt Vogel, Oreste Segatto	7
15	Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research 2019 ·Cancers ·Oihane Erice, Adrián Vallejo, Mariano Ponz‐Sarvisé, Michael Saborowski, Arndt Vogel, Diego F. Calvisi, Anna Saborowski, Silvestre Vicent	6
16	The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies 2019 ·Targeted Oncology ·Jens U. Marquardt, Anna Saborowski, Carolin Czauderna, Arndt Vogel	21
17	Cholangiocellular Carcinoma 2017 ·Digestion ·Arndt Vogel, Anna Saborowski	16
18	A modular and flexible ESC-based mouse model of pancreatic cancer 2014 ·Genes & Development ·Michael Saborowski, Anna Saborowski, John P. Morris, Benedikt Bosbach, Lukas E. Dow, Jerry Pelletier, David S. Klimstra, Scott W. Lowe	52
19	Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors 2014 ·Cancer Cell ·Piro Lito, Anna Saborowski, Jingyin Yue, Martha Solomon, Eric W. Joseph, Sunyana Gadal, Michael Saborowski, Edward R. Kastenhuber, Christof Fellmann, Kazuhiro Ohara, Kenji Morikami, Takaaki Miura, Christine Lukacs, Nobuya Ishii, Scott W. Lowe, Neal Rosen	222
20	Unilaterale akrale Nekrosen als Abortivform einer palmoplantaren Erythrodysästhesie 2006 ·Der Hautarzt ·Cornelia Sauter, Anna Saborowski, H.M. Ockenfels	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact